DaMa Pharmaceutical

Dama Pharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the discovery and development of precision oncology therapeutics. The company focuses on the DNA Damage Response (DDR) pathway and the principle of synthetic lethality to treat various cancers. Its lead candidate, DM-001, is a potent PARP inhibitor currently undergoing clinical evaluation for solid tumors such as ovarian and breast cancer. Dama's pipeline also includes DM-002, an ATR inhibitor, and other programs targeting key enzymes in the DNA repair network. Founded by the renowned chemist Dr. Dawei Ma, the company leverages deep medicinal chemistry expertise to advance its portfolio of small molecule drugs. The company is backed by prominent investors including Qiming Venture Partners and Hillhouse Capital.